Company intelligence / Profile preview

INDIGO Biosciences

State College, Pennsylvania, United Statesindigobiosciences.com ↗

Ownership: Private
Employees: ~18
Development stage: Other

Overview

INDIGO Biosciences provides a large portfolio of validated cell-based reporter gene assays—primarily targeting nuclear receptors—and in vitro toxicology solutions. Their technologies enable rapid compound screening with high sensitivity and reproducibility. The company does not develop therapeutics themselves but supports preclinical research across pharma/biotech sectors.

No clinical results apply as they do not have a therapeutic pipeline.

Therapeutic areas: Other
Modalities: Small moleculeCell-based assay kitsReporter gene assaysBiologic
Industry: Drug Discovery Services

Partnerships

Not specifically listed in public sources; serves pharmaceutical companies, biotech firms, government agencies & academic labs globally

Beyond the preview

Go deeper on INDIGO Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INDIGO Biosciences.

Explore the full profile